FR22C1007I2 - OPTIMIZED ANTIBODIES TARGETING CD19 - Google Patents
OPTIMIZED ANTIBODIES TARGETING CD19Info
- Publication number
- FR22C1007I2 FR22C1007I2 FR22C1007C FR22C1007C FR22C1007I2 FR 22C1007 I2 FR22C1007 I2 FR 22C1007I2 FR 22C1007 C FR22C1007 C FR 22C1007C FR 22C1007 C FR22C1007 C FR 22C1007C FR 22C1007 I2 FR22C1007 I2 FR 22C1007I2
- Authority
- FR
- France
- Prior art keywords
- antibodies targeting
- optimized antibodies
- optimized
- targeting
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82236206P | 2006-08-14 | 2006-08-14 | |
EP11173336.6A EP2383297B8 (en) | 2006-08-14 | 2007-08-14 | Optimized antibodies that target CD19 |
Publications (2)
Publication Number | Publication Date |
---|---|
FR22C1007I1 FR22C1007I1 (en) | 2022-04-29 |
FR22C1007I2 true FR22C1007I2 (en) | 2022-12-30 |
Family
ID=39083071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR22C1007C Active FR22C1007I2 (en) | 2006-08-14 | 2022-02-18 | OPTIMIZED ANTIBODIES TARGETING CD19 |
Country Status (20)
Country | Link |
---|---|
US (7) | US8524867B2 (en) |
EP (2) | EP2383297B8 (en) |
JP (4) | JP5825756B2 (en) |
AU (1) | AU2007285976B2 (en) |
CA (1) | CA2658557C (en) |
DK (2) | DK2383297T5 (en) |
ES (2) | ES2457072T3 (en) |
FI (1) | FIC20220006I1 (en) |
FR (1) | FR22C1007I2 (en) |
HK (1) | HK1131168A1 (en) |
HR (2) | HRP20130314T2 (en) |
HU (1) | HUS2200007I1 (en) |
LT (1) | LTPA2022503I1 (en) |
ME (1) | ME01786B (en) |
NL (1) | NL301163I2 (en) |
PL (2) | PL2059536T3 (en) |
PT (2) | PT2059536E (en) |
RS (2) | RS53263B (en) |
SI (2) | SI2059536T1 (en) |
WO (1) | WO2008022152A2 (en) |
Families Citing this family (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5624276B2 (en) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | Methods for controlling blood kinetics of antibodies |
WO2008022152A2 (en) * | 2006-08-14 | 2008-02-21 | Xencor, Inc. | Optimized antibodies that target cd19 |
EP3392273A1 (en) | 2007-05-30 | 2018-10-24 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
JP5334319B2 (en) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Method for modifying isoelectric point of antibody by amino acid substitution of CDR |
KR102225009B1 (en) | 2007-09-26 | 2021-03-08 | 추가이 세이야쿠 가부시키가이샤 | Modified antibody constant region |
JP5727786B2 (en) | 2007-10-19 | 2015-06-03 | シアトル ジェネティクス,インコーポレーテッド | CD19 binding substance and use thereof |
KR20220162801A (en) | 2008-04-11 | 2022-12-08 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
CN102076355B (en) | 2008-04-29 | 2014-05-07 | Abbvie公司 | Dual varistructure domain immunoglobulins and uses thereof |
EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9109026B2 (en) | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
KR20110031369A (en) | 2008-07-08 | 2011-03-25 | 아보트 러보러터리즈 | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
KR101695329B1 (en) * | 2008-11-07 | 2017-01-23 | 암젠 리서치 (뮌헨) 게엠베하 | Treatment of Pediatric Acute Lymphoblastic Leukemia |
LT2982696T (en) | 2008-11-07 | 2019-06-10 | Amgen Research (Munich) Gmbh | Treatment of acute lymphoblastic leukemia |
ES2661074T3 (en) | 2009-06-02 | 2018-03-27 | Regeneron Pharmaceuticals, Inc. | Fucosylation deficient cells |
CN102666875A (en) | 2009-10-15 | 2012-09-12 | 雅培制药有限公司 | Dual variable domain immunoglobulins and uses thereof |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
CA2799595C (en) | 2010-05-27 | 2022-08-16 | Merck Sharp & Dohme Corp. | Method for preparing antibodies having improved properties |
EP2409989A1 (en) * | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Method to improve glycosylation profile for antibody |
EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
BR112013002578A2 (en) | 2010-08-03 | 2019-05-14 | Abbvie Inc. | double variable domain immunoglobins and their uses |
AU2011293253B2 (en) | 2010-08-26 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
EP2679681B2 (en) | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific FC antibody |
EP4011913A1 (en) * | 2011-06-30 | 2022-06-15 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
SI2744826T1 (en) | 2011-08-16 | 2022-05-31 | Morphosys Ag | Combination therapy with an anti-cd19 antibody and a purine analog |
ES2909722T3 (en) | 2011-08-16 | 2022-05-10 | Morphosys Ag | Combination therapy with an anti-CD19 antibody and a nitrogen mustard |
TW201817744A (en) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
US20140335089A1 (en) | 2011-09-30 | 2014-11-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting elimination of antigens |
WO2013047748A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
WO2013081143A1 (en) | 2011-11-30 | 2013-06-06 | 中外製薬株式会社 | Drug containing carrier into cell for forming immune complex |
CA3111357A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
TW201333035A (en) | 2011-12-30 | 2013-08-16 | Abbvie Inc | Dual specific binding proteins directed against IL-13 and/or IL-17 |
CN107266564A (en) | 2012-02-24 | 2017-10-20 | 中外制药株式会社 | Promote the antigen binding molecules that antigen is eliminated via Fc γ IIB |
US20150044168A1 (en) * | 2012-03-12 | 2015-02-12 | Medlmmune, Llc | Treatment of Multiple Sclerosis With Anti-CD19 Antibody |
JP2015517655A (en) * | 2012-05-01 | 2015-06-22 | ザ チルドレンズ ホスピタル オブフィラデルフィア | Compositions and methods for treating B-lymphoid malignancy |
WO2013176916A1 (en) | 2012-05-25 | 2013-11-28 | Roman Galetto | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
JP6628966B2 (en) | 2012-06-14 | 2020-01-15 | 中外製薬株式会社 | Antigen binding molecule containing an altered Fc region |
US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
BR112015001955A2 (en) | 2012-08-24 | 2017-11-07 | Chugai Pharmaceutical Co Ltd | fcgamariib specific fc region variant |
CN104837502B (en) | 2012-10-12 | 2018-08-10 | 麦迪穆有限责任公司 | Pyrrolobenzodiazepines Zhuo and its conjugate |
DK2906298T3 (en) | 2012-10-12 | 2018-12-17 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
CN105102068B (en) | 2012-10-12 | 2018-06-01 | Adc疗法责任有限公司 | Pyrrolobenzodiazepines Zhuo-antibody conjugates |
MY194330A (en) | 2012-11-01 | 2022-11-28 | Abbvie Inc | Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof |
BR112015010722A2 (en) | 2012-11-09 | 2017-08-22 | Pfizer | SPECIFIC GROWTH FACTOR ANTIBODIES DERIVED FROM ISOFORM B PLATELETS AND COMPOSITIONS AND USES THEREOF |
ES2876009T3 (en) | 2012-12-27 | 2021-11-11 | Chugai Pharmaceutical Co Ltd | Heterodimerized polypeptide |
US9409977B2 (en) | 2013-03-12 | 2016-08-09 | Decimmune Therapeutics, Inc. | Humanized, anti-N2 antibodies |
JP6444902B2 (en) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドMedImmune Limited | Pyrrolobenzodiazepine and its conjugates |
CN105324396A (en) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | Dual specific binding proteins directed against il-1 beta and il-17 |
US9561291B2 (en) * | 2013-03-15 | 2017-02-07 | Imre Kovesdi | Methods of targeting T-cells to tumors |
WO2014163101A1 (en) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Fc region variant |
US11077144B2 (en) | 2013-05-13 | 2021-08-03 | Cellectis | CD19 specific chimeric antigen receptor and uses thereof |
EP4364809A2 (en) * | 2013-05-13 | 2024-05-08 | Cellectis | Cd19 specific chimeric antigen receptor and uses thereof |
WO2015046467A1 (en) | 2013-09-27 | 2015-04-02 | 中外製薬株式会社 | Method for producing polypeptide heteromultimer |
WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
SG10201810298VA (en) | 2013-11-13 | 2018-12-28 | Pfizer | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
KR20150132581A (en) * | 2013-12-31 | 2015-11-25 | 재단법인 생물기술개발중심 | Anti-vegf antibodies and use thereof |
WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
CA2951427A1 (en) * | 2014-06-16 | 2015-12-23 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
IL249533A0 (en) * | 2014-06-16 | 2017-02-28 | Xencor Inc | Treatment for chronic lymphocytic leukemia (cll) |
US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
USD791796S1 (en) * | 2014-09-11 | 2017-07-11 | Express Scripts, Inc. | Display screen with a graphical user interface |
USD801353S1 (en) * | 2014-09-11 | 2017-10-31 | Express Scripts, Inc. | Display screen with a graphical user interface |
USD791797S1 (en) * | 2014-09-11 | 2017-07-11 | Express Scripts, Inc. | Display screen with a graphical user interface |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
EP3489256B1 (en) | 2014-11-14 | 2021-03-17 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
KR20180054923A (en) | 2014-12-19 | 2018-05-24 | 추가이 세이야쿠 가부시키가이샤 | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
MX2017008978A (en) | 2015-02-05 | 2017-10-25 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof. |
CN114751989A (en) | 2015-03-31 | 2022-07-15 | 豪夫迈·罗氏有限公司 | Antigen binding molecules comprising trimeric TNF family ligands |
AR104368A1 (en) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | ANTI-CD20- / ANTI-BAFF BIESPECTIFIC ANTIBODIES |
CN107660151B (en) | 2015-05-26 | 2022-03-11 | 莫佛塞斯公司 | Combination of an anti-CD 19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
US11066481B2 (en) | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
MX2018002241A (en) | 2015-08-21 | 2018-03-23 | Morphosys Ag | Combinations and uses thereof. |
MA44909A (en) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | THERAPEUTIC ASSOCIATION OF A CD19 INHIBITOR AND A BTK INHIBITOR |
AR106188A1 (en) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE |
BR112018006350A2 (en) * | 2015-10-02 | 2018-10-09 | Hoffmann La Roche | antibodies, polynucleotide, vector, host cell, method for producing antibody, pharmaceutical formulation and use of antibody |
US10138298B2 (en) | 2015-10-23 | 2018-11-27 | The Regents Of The University Of California | Anti-IL-2 antibodies and compositions and uses thereof |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN109313194B (en) | 2016-05-30 | 2022-11-04 | 莫佛塞斯公司 | Methods of predicting therapeutic benefit of CD19antibody therapy in a patient |
HUE064454T2 (en) | 2016-06-08 | 2024-03-28 | Xencor Inc | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
PT3475303T (en) * | 2016-06-27 | 2021-06-25 | Morphosys Ag | Anti-cd19 antibody formulations |
US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
EP3525829A1 (en) | 2016-10-11 | 2019-08-21 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
RS62036B1 (en) | 2016-10-28 | 2021-07-30 | Morphosys Ag | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
RS61795B1 (en) | 2017-02-08 | 2021-06-30 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
JP2020517609A (en) | 2017-04-18 | 2020-06-18 | メディミューン リミテッド | Pyrrolobenzodiazepine complex |
SG11201909715VA (en) | 2017-05-31 | 2019-11-28 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
JP7279011B2 (en) | 2017-07-10 | 2023-05-22 | インターナショナル-ドラッグ-ディベロップメント-バイオテック | Treatment of B-cell malignancies using non-fucosylated pro-apoptotic anti-CD19 antibodies in combination with anti-CD20 antibodies or chemotherapeutic agents |
WO2019034764A1 (en) | 2017-08-18 | 2019-02-21 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
EP3684820A4 (en) * | 2017-09-21 | 2021-05-26 | Wuxi Biologics (Cayman) Inc. | Novel anti-cd19 antibodies |
MA51154A (en) * | 2017-12-15 | 2020-10-21 | Aleta Biotherapeutics Inc | CD19 VARIANTS |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
CN112119090B (en) | 2018-03-15 | 2023-01-13 | 中外制药株式会社 | Anti-dengue virus antibodies cross-reactive to Zika virus and methods of use |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CN113286616A (en) | 2018-05-23 | 2021-08-20 | Adc治疗有限公司 | Molecular adjuvant |
CA3102398A1 (en) | 2018-06-03 | 2019-12-12 | Lamkap Bio Beta Ltd. | Bispecific antibodies against ceacam5 and cd47 |
JP2022515543A (en) | 2018-12-30 | 2022-02-18 | エフ.ホフマン-ラ ロシュ アーゲー | Anti-rabbit CD19 antibody and how to use |
CN114072424A (en) | 2019-05-03 | 2022-02-18 | 莫佛塞斯公司 | anti-CD 19 therapy in patients with limited number of NK cells |
JP2022550435A (en) | 2019-10-04 | 2022-12-01 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | Methods for improved therapeutic use of recombinant AAV |
MX2022005033A (en) * | 2019-10-31 | 2022-09-09 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells. |
MX2022005031A (en) | 2019-10-31 | 2022-07-27 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma. |
CA3158985A1 (en) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Sequential anti-cd19 therapy |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
CA3164818A1 (en) | 2019-12-18 | 2021-06-24 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
EP3869302A1 (en) | 2020-02-18 | 2021-08-25 | Bayerische Motoren Werke Aktiengesellschaft | Vehicle, apparatus and method to reduce the occurence of motion sickness |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
EP4168449A1 (en) | 2020-06-22 | 2023-04-26 | MorphoSys AG | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
AU2021300429A1 (en) | 2020-07-02 | 2023-02-16 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
EP4225794A1 (en) | 2020-10-06 | 2023-08-16 | Xencor, Inc. | Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle) |
WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
JP2023551519A (en) | 2020-11-30 | 2023-12-08 | インサイト・コーポレイション | Combination therapy of anti-CD19 antibody and parsaclisib |
WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
WO2022117799A2 (en) | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
PE20231386A1 (en) | 2020-12-18 | 2023-09-12 | Lamkap Bio Beta Ltd | BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
TW202302589A (en) | 2021-02-25 | 2023-01-16 | 美商英塞特公司 | Spirocyclic lactams as jak2 v617f inhibitors |
EP4326288A1 (en) | 2021-04-21 | 2024-02-28 | Indapta Therapeutics, Inc. | Methods of treatment and dosing of natural killer cell compositions |
CA3221735A1 (en) | 2021-06-18 | 2022-12-22 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
TW202334231A (en) | 2021-12-22 | 2023-09-01 | 德商莫菲西斯公司 | Treatment paradigm for an anti-cd19 antibody therapy |
US20230295124A1 (en) | 2022-03-17 | 2023-09-21 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
TW202346359A (en) | 2022-04-15 | 2023-12-01 | 美商凱維那醫療公司 | Methods and compositions for treating autoimmune disease |
WO2023240064A1 (en) | 2022-06-08 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
WO2023242351A1 (en) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ag | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
WO2024038115A1 (en) | 2022-08-17 | 2024-02-22 | Morphosys Ag | Therapy comprising anti-cd19 antibody and ezh2 modulators |
WO2024086273A1 (en) | 2022-10-21 | 2024-04-25 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
Family Cites Families (211)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US618965A (en) * | 1899-02-07 | Filter | ||
US2228904A (en) | 1939-05-10 | 1941-01-14 | Bjorkman Hugo Leonard | Wrench |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
DE3751996T2 (en) | 1986-05-29 | 1997-07-03 | Ilexus Pty Ltd | Polynucleotide sequences coding for the human FC RECEPTOR FOR IMMUNOGLOBULIN |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
PT88641B (en) | 1987-10-02 | 1993-04-30 | Genentech Inc | METHOD FOR PREPARING A VARIETY OF ADHESION |
US5576184A (en) | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
US5681566A (en) | 1988-10-24 | 1997-10-28 | 3I Research Exploitation Limited | Antibody conjugates with two or more covalently linked FC regions |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JP3051411B2 (en) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | Novel DNA and expression plasmid containing it |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2045150A1 (en) | 1989-11-07 | 1991-05-08 | Walt W. Shuford | Oligomeric immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
AU7566991A (en) | 1990-03-14 | 1991-10-10 | Biomembrane Institute, The | Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders |
WO1991019515A1 (en) | 1990-06-21 | 1991-12-26 | The Board Of Trustees Of The Leland Stanford Junior University | Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity |
US5198342A (en) | 1990-07-05 | 1993-03-30 | Immunex Corporation | DNA encoding IgA Fc receptors |
KR930702029A (en) | 1990-08-31 | 1993-09-08 | 스티븐 체스노프 | Homozygous Immunoglobulins |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5623053A (en) | 1992-01-10 | 1997-04-22 | California Institute Of Technology | Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5 |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5686072A (en) * | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
ATE199392T1 (en) | 1992-12-04 | 2001-03-15 | Medical Res Council | MULTIVALENT AND MULTI-SPECIFIC BINDING PROTEINS, THEIR PRODUCTION AND USE |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
GB2301366B (en) | 1994-03-29 | 1998-07-29 | Celltech Therapeutics Ltd | Antibodies against E-selectin |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
CN1068323C (en) | 1994-07-21 | 2001-07-11 | 阿克佐诺贝尔公司 | Cyclic ketone peroxide formulations |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
DK1323346T3 (en) | 1995-01-17 | 2006-10-30 | Brigham & Womens Hospital | Receptor-specific transport of immunogens through the epithelium |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
DK0817775T3 (en) | 1995-03-30 | 2001-11-19 | Pfizer | quinazoline |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US6444789B1 (en) | 1995-05-03 | 2002-09-03 | Applied Research Systems Ars Holding N.V. | CD16-II variants |
EP0835134A1 (en) * | 1995-05-17 | 1998-04-15 | Regents Of The University Of Minnesota | Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies |
US6365161B1 (en) | 1995-06-07 | 2002-04-02 | Medarex, Inc. | Therapeutic compounds comprised of anti-FC receptor binding agents |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
CA2249320C (en) | 1996-03-20 | 2008-12-23 | Immunomedics, Inc. | Glycosylated humanized b-cell specific antibodies |
SI0892789T2 (en) | 1996-04-12 | 2010-03-31 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
ATE253593T1 (en) | 1996-07-16 | 2003-11-15 | Plueckthun Andreas Prof Dr | IMMUNOGLOBULIN SUPERFAMILY DOMAINS AND FRAGMENTS WITH INCREASED SOLUBILITY |
CA2262405A1 (en) | 1996-08-02 | 1998-02-12 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
AU5927398A (en) | 1997-01-21 | 1998-08-07 | Human Genome Sciences, Inc. | Fc receptors and polypeptides |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
UA73073C2 (en) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Substituted 3-cyan chinolines |
US6188965B1 (en) | 1997-04-11 | 2001-02-13 | California Institute Of Technology | Apparatus and method for automated protein design |
EP1255209A3 (en) | 1997-04-11 | 2009-02-11 | California Institute Of Technology | Apparatus and method for automated protein design |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US20040191256A1 (en) | 1997-06-24 | 2004-09-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
US20030105294A1 (en) | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2532910T3 (en) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Antibody variants and fragments thereof |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
WO1999054440A1 (en) | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
DE19819846B4 (en) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalent antibody constructs |
CA2331607A1 (en) | 1998-05-06 | 1999-11-11 | Temple University - Of The Commonwealth System Of Higher Education | Reversal of proinflammatory response by ligating the macrophage fc.gamma.ri receptor |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US6306926B1 (en) | 1998-10-07 | 2001-10-23 | 3M Innovative Properties Company | Radiopaque cationically polymerizable compositions comprising a radiopacifying filler, and method for polymerizing same |
US20020048772A1 (en) | 2000-02-10 | 2002-04-25 | Dahiyat Bassil I. | Protein design automation for protein libraries |
US20030049654A1 (en) | 1998-10-16 | 2003-03-13 | Xencor | Protein design automation for protein libraries |
US6403312B1 (en) | 1998-10-16 | 2002-06-11 | Xencor | Protein design automatic for protein libraries |
JP2003527072A (en) | 1998-10-16 | 2003-09-16 | ゼンコー | Protein design automation for protein libraries |
US7315786B2 (en) | 1998-10-16 | 2008-01-01 | Xencor | Protein design automation for protein libraries |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (en) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polypeptide comprising an Fc region of variant human IgG1 |
ES2568899T3 (en) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedure to control the activity of an immunofunctional molecule |
MXPA01011279A (en) | 1999-05-07 | 2002-07-02 | Genentech Inc | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers. |
AU782160B2 (en) | 1999-06-09 | 2005-07-07 | Immunomedics Inc. | Immunotherapy of autoimmune disorders using antibodies which target B-cells |
US6638515B2 (en) | 1999-09-07 | 2003-10-28 | Walter Schubert | Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using protein V |
JP4668498B2 (en) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | Method for producing polypeptide |
CA2393126C (en) | 1999-11-29 | 2016-05-24 | The Trustees Of Columbia University In The City Of New York | Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
DE19958134C2 (en) | 1999-12-02 | 2003-05-15 | Koenig & Bauer Ag | suction roll |
EP1254177A1 (en) | 2000-02-03 | 2002-11-06 | Hammarström, Lennart | RUMINANT MHC CLASS I-LIKE Fc RECEPTORS |
AU5168701A (en) | 2000-02-10 | 2001-08-20 | Xencor | Protein design automation for protein libraries |
PL357939A1 (en) | 2000-04-11 | 2004-08-09 | Genentech, Inc. | Multivalent antibodies and uses therefor |
EP1272526A4 (en) | 2000-04-13 | 2004-10-13 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
US6358733B1 (en) | 2000-05-19 | 2002-03-19 | Apolife, Inc. | Expression of heterologous multi-domain proteins in yeast |
EP1296714B1 (en) | 2000-06-22 | 2009-08-26 | University Of Iowa Research Foundation | Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer. |
WO2002025588A2 (en) | 2000-09-21 | 2002-03-28 | Md Online Inc. | Medical image processing systems |
CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
ES2651952T3 (en) | 2000-10-06 | 2018-01-30 | Kyowa Hakko Kirin Co., Ltd. | Cells that produce antibody compositions |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
WO2002043658A2 (en) | 2000-11-06 | 2002-06-06 | The Jackson Laboratory | Fcrn-based therapeutics for the treatment of auto-immune disorders |
US7235643B2 (en) | 2000-11-07 | 2007-06-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with high affinity |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
PT1355919E (en) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Molecules with extended half-lives, compositions and uses thereof |
AU2002245142B2 (en) | 2000-12-14 | 2007-07-05 | Genentech, Inc. | Prokaryotically produced antibodies and uses thereof |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP1358337A1 (en) | 2001-01-30 | 2003-11-05 | Degussa AG | Nucleotide sequences which code for the otsa gene of c. glutamicum |
CA2436180C (en) | 2001-01-31 | 2011-11-08 | Idec Pharmaceutical Corporation | Immunoregulatory antibodies and uses thereof |
US20030103971A1 (en) | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
US20040136908A1 (en) | 2001-04-09 | 2004-07-15 | Olson William C. | Anti-cd19 immunotoxins |
CN101671335A (en) | 2001-05-31 | 2010-03-17 | 梅达莱克斯公司 | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
GB0118662D0 (en) | 2001-07-31 | 2001-09-19 | Univ Southampton | Binding agents |
HUP0700103A3 (en) | 2001-08-03 | 2012-09-28 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
EP1432980A4 (en) | 2001-08-10 | 2006-04-12 | Xencor Inc | Protein design automation for protein libraries |
US7255858B2 (en) | 2001-08-10 | 2007-08-14 | University Of Virginia Patent Foundation | Enhancing the efficacy of immunotherapies by supplementing with complement |
EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
CN100423777C (en) | 2001-10-25 | 2008-10-08 | 杰南技术公司 | Glycoprotein compositions |
ES2283368T3 (en) | 2001-11-14 | 2007-11-01 | Affimed Therapeutics Ag | ANTI-CD19 AND ANTI-CD16 BIESPECIFIC ANTIBODIES AND USES OF THE SAME. |
US6911321B2 (en) | 2001-12-19 | 2005-06-28 | Genentech, Inc. | Non-human primate Fc receptors and methods of use |
EP1573002A4 (en) | 2002-02-11 | 2008-07-16 | Genentech Inc | Antibody variants with faster antigen association rates |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
US20080260731A1 (en) | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
CA2479212A1 (en) | 2002-03-15 | 2003-09-25 | Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
EP1490085A2 (en) | 2002-03-25 | 2004-12-29 | Uab Research Foundation | Fc receptor homolog, reagents, and uses thereof |
EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO Fc GAMMA RECEPTOR IIIa |
EP1354600A1 (en) | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
AU2003232081B2 (en) | 2002-07-03 | 2009-02-05 | Brandeis University | Central airway administration for systemic delivery of therapeutics |
EP1572091A4 (en) | 2002-07-09 | 2008-03-05 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
DK1534335T4 (en) | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
WO2004022717A2 (en) | 2002-09-05 | 2004-03-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen |
WO2004024889A2 (en) | 2002-09-16 | 2004-03-25 | Elusys Therapeutics, Inc. | Production of bispecific molecules using polyethylene glycol linkers |
SI1562972T1 (en) | 2002-10-15 | 2010-12-31 | Facet Biotech Corp | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
EP1944320A1 (en) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
SI2335725T1 (en) | 2003-04-04 | 2017-01-31 | Genentech, Inc. | High concentration antibody and protein formulations |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
BRPI0410260A (en) | 2003-05-14 | 2006-05-16 | Immunogen Inc | drug conjugate composition |
AR044388A1 (en) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | CD20 UNION MOLECULES |
JP2007501021A (en) | 2003-05-30 | 2007-01-25 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Antibodies and fusion proteins containing genetically engineered constant regions |
EP1629012B1 (en) | 2003-05-31 | 2018-11-28 | Amgen Research (Munich) GmbH | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
DE602004011770T2 (en) | 2003-06-12 | 2009-02-05 | Eli Lilly And Co., Indianapolis | FUSION PROTEIN |
US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
US20050033029A1 (en) | 2003-06-30 | 2005-02-10 | Jin Lu | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
HUE033129T2 (en) | 2003-07-24 | 2017-11-28 | Innate Pharma Sa | Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds |
WO2005011376A2 (en) | 2003-07-26 | 2005-02-10 | Biogen Idec Ma Inc | Altered antibodies having improved antigen-binding affinity |
JP4733635B2 (en) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | Anti-CD19 antibody |
EP2434420A3 (en) | 2003-08-01 | 2012-07-25 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
US20050152894A1 (en) | 2003-09-05 | 2005-07-14 | Genentech, Inc. | Antibodies with altered effector functions |
CA2579635A1 (en) | 2003-09-10 | 2005-03-17 | Baxter International Inc. | Peptides that inhibit complement activation |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
US10000574B2 (en) | 2003-11-28 | 2018-06-19 | Amgen Research (Munich) Gmbh | Compositions comprising polypeptides |
SI1706424T1 (en) | 2004-01-12 | 2010-01-29 | Applied Molecular Evolution | Fc region variants |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
KR100545720B1 (en) | 2004-05-31 | 2006-01-24 | 메덱스젠 주식회사 | Glycosylated Immunoglobulin and Immunoadhesin comprising the same |
MX2007000891A (en) | 2004-07-23 | 2007-04-18 | Genentech Inc | Crystallization of antibodies or fragments thereof. |
WO2006047350A2 (en) * | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
CA2597924C (en) | 2005-02-15 | 2018-10-02 | Duke University | Anti-cd19 antibodies and uses in oncology |
WO2006121852A2 (en) | 2005-05-05 | 2006-11-16 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
EP1904101A4 (en) | 2005-06-08 | 2011-06-15 | Univ Duke | Anti-cd19 antibody therapy for the transplantation |
WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
CA2633594C (en) | 2005-12-16 | 2021-10-26 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
CA2635623C (en) | 2005-12-30 | 2015-02-17 | Michael Super | Anti-cd19 antibodies with reduced immunogenicity |
US20070166306A1 (en) | 2006-01-17 | 2007-07-19 | Fey Georg H M | Anti-CD19 antibody composition and method |
US20070178103A1 (en) | 2006-01-30 | 2007-08-02 | Fey Georg H | CD19-specific immunotoxin and treatment method |
WO2008022152A2 (en) | 2006-08-14 | 2008-02-21 | Xencor, Inc. | Optimized antibodies that target cd19 |
ATE551071T1 (en) | 2006-09-08 | 2012-04-15 | Medimmune Llc | HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATION AND AUTOIMMUNE DISEASES |
US20080267977A1 (en) | 2007-04-26 | 2008-10-30 | Friedrich-Alexander University Of Erlangen-Nuremberg | Combined immunological agent and sensitizing agent for the treatment of cancer |
EP3392273A1 (en) * | 2007-05-30 | 2018-10-24 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
US9098105B2 (en) | 2012-08-24 | 2015-08-04 | Avago Technologies General Ip (Singapore) Pte. Ltd. | Dynamic Y-buffer size adjustment for retained sector reprocessing |
US9679104B2 (en) | 2013-01-17 | 2017-06-13 | Edico Genome, Corp. | Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform |
US9703321B2 (en) | 2013-07-09 | 2017-07-11 | I-Blades, Inc. | Snap on wearable module |
US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2007
- 2007-08-14 WO PCT/US2007/075932 patent/WO2008022152A2/en active Application Filing
- 2007-08-14 EP EP11173336.6A patent/EP2383297B8/en active Active
- 2007-08-14 SI SI200731437T patent/SI2059536T1/en unknown
- 2007-08-14 PT PT78409539T patent/PT2059536E/en unknown
- 2007-08-14 JP JP2009524772A patent/JP5825756B2/en active Active
- 2007-08-14 ME MEP-2014-35A patent/ME01786B/en unknown
- 2007-08-14 DK DK11173336.6T patent/DK2383297T5/en active
- 2007-08-14 SI SI200731159T patent/SI2383297T1/en unknown
- 2007-08-14 PT PT111733366T patent/PT2383297E/en unknown
- 2007-08-14 ES ES07840953.9T patent/ES2457072T3/en active Active
- 2007-08-14 ES ES11173336T patent/ES2402591T3/en active Active
- 2007-08-14 AU AU2007285976A patent/AU2007285976B2/en active Active
- 2007-08-14 EP EP07840953.9A patent/EP2059536B1/en active Active
- 2007-08-14 US US12/377,251 patent/US8524867B2/en active Active
- 2007-08-14 DK DK07840953.9T patent/DK2059536T3/en active
- 2007-08-14 PL PL07840953T patent/PL2059536T3/en unknown
- 2007-08-14 CA CA2658557A patent/CA2658557C/en active Active
- 2007-08-14 RS RS20140165A patent/RS53263B/en unknown
- 2007-08-14 RS RS20130134A patent/RS52775B9/en unknown
- 2007-08-14 PL PL11173336T patent/PL2383297T3/en unknown
-
2009
- 2009-11-20 HK HK09110913.4A patent/HK1131168A1/en unknown
-
2011
- 2011-05-06 JP JP2011103488A patent/JP5645747B2/en active Active
- 2011-08-30 US US13/221,811 patent/US20120082664A1/en not_active Abandoned
-
2013
- 2013-04-05 HR HRP20130314TT patent/HRP20130314T2/en unknown
- 2013-06-04 JP JP2013118273A patent/JP2013177443A/en active Pending
- 2013-08-05 US US13/959,587 patent/US9803020B2/en active Active
- 2013-09-10 US US14/023,305 patent/US20140112916A1/en not_active Abandoned
-
2014
- 2014-04-07 HR HRP20140331TT patent/HRP20140331T1/en unknown
-
2015
- 2015-09-11 JP JP2015179854A patent/JP2015221839A/en active Pending
-
2017
- 2017-09-22 US US15/712,918 patent/US10626182B2/en active Active
-
2020
- 2020-04-01 US US16/837,678 patent/US11618788B2/en active Active
-
2022
- 2022-02-18 HU HUS2200007C patent/HUS2200007I1/en unknown
- 2022-02-18 FR FR22C1007C patent/FR22C1007I2/en active Active
- 2022-02-21 FI FIC20220006C patent/FIC20220006I1/en unknown
- 2022-02-22 NL NL301163C patent/NL301163I2/en unknown
- 2022-02-24 LT LTPA2022503C patent/LTPA2022503I1/lt unknown
-
2023
- 2023-02-21 US US18/172,196 patent/US20230340144A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR22C1007I2 (en) | OPTIMIZED ANTIBODIES TARGETING CD19 | |
DK1912671T3 (en) | BETA-glucuronide-LINKER-drug conjugates | |
FR2896407B3 (en) | walker | |
NO20084222L (en) | Targeted binding compounds targeting uPAR and their use | |
DK2371948T5 (en) | lipase variants | |
DK2444807T3 (en) | MONO AND DINITROPYRAZOLHAPTEN CONJUGATES | |
EP2041175A4 (en) | Targeted immune conjugates | |
DK1907748T3 (en) | Pipe | |
DE112007002873A5 (en) | Decoupler assembly | |
DK2359864T3 (en) | Targeting vector phospholipid conjugates | |
BRPI0923047A2 (en) | "protein-oligosaccharide conjugates". | |
DK2052011T3 (en) | TARGETED POLYLYSIN-DENDRIMER-THERAPEUTIC SUBSTANCE | |
EP1948600A4 (en) | Liver targeted conjugates | |
ATE410929T1 (en) | IMPROVED DRINK | |
FR2887945B1 (en) | DECOUPLER SLEEVE | |
BRPI0819765A2 (en) | Anti-RG-1 Antibody Conjugates | |
DE112007001320A5 (en) | wave | |
DE502007001092D1 (en) | silencer ground | |
BRPI0916092A2 (en) | "specific anti-her4 antibody isoforms" | |
AT502772A3 (en) | TURN PLOW | |
DE602006016398D1 (en) | drink | |
FI20065208A0 (en) | peptide conjugates | |
ATE372220T1 (en) | CLUTCH BODY | |
ITAL20050011A1 (en) | EASY IRON | |
ES1063132Y (en) | BIB |